Ira Pastan

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
    Bangalore K Sathyanarayana
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    BMC Struct Biol 9:1. 2009
  2. ncbi Immunotoxin therapy of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Nat Rev Cancer 6:559-65. 2006
  3. ncbi An NIH career: from bedside to basic research and back
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892-4264, USA
    J Biol Chem 280:18553-7. 2005
  4. ncbi Immunotoxin treatment of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 58:221-37. 2007
  5. ncbi New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
  6. ncbi Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 11:87-96. 2005
  7. ncbi Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, MSC 4264, 37 Convent Drive Room 5106, Bethesda, MD 20892 4264, USA
    Gene 337:45-53. 2004
  8. ncbi Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 177:8822-34. 2006
  9. ncbi A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice
    Johanna K Hansen
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:297-304. 2010
  10. ncbi An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Proc Natl Acad Sci U S A 105:11311-6. 2008

Detail Information

Publications107 found, 100 shown here

  1. ncbi Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
    Bangalore K Sathyanarayana
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    BMC Struct Biol 9:1. 2009
    ..Mesothelin has been reported to be homologous to the deafness-related inner ear proteins otoancorin and stereocilin, for neither of which the three-dimensional structure is known...
  2. ncbi Immunotoxin therapy of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Nat Rev Cancer 6:559-65. 2006
    ..Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy...
  3. ncbi An NIH career: from bedside to basic research and back
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892-4264, USA
    J Biol Chem 280:18553-7. 2005
  4. ncbi Immunotoxin treatment of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 58:221-37. 2007
    ..Strategies to overcome these limitations are being pursued...
  5. ncbi New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy
    Vittore Cereda
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 59:63-71. 2010
    ..These studies thus identify NGEP as a potential target for T cell-mediated immunotherapy of prostate cancer...
  6. ncbi Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 11:87-96. 2005
    ..To study the expression of the IRTA2 gene product, we produced monoclonal antibodies (MAbs) specific to IRTA2...
  7. ncbi Five POTE paralogs and their splice variants are expressed in human prostate and encode proteins of different lengths
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, MSC 4264, 37 Convent Drive Room 5106, Bethesda, MD 20892 4264, USA
    Gene 337:45-53. 2004
    ..We also detect a noncoding transcript expressed on the opposite strand from POTE on chromosome 14 or 22. We speculate that POTE has an important signaling function in the reproductive system...
  8. ncbi Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 177:8822-34. 2006
    ..Our results indicate that a relatively small number of discrete immunogenic sites are associated with PE38, most of which can be eliminated by point mutations...
  9. ncbi A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice
    Johanna K Hansen
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:297-304. 2010
    ..Future studies will determine if these properties carry over to humans with cancer...
  10. ncbi An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Proc Natl Acad Sci U S A 105:11311-6. 2008
    ..Elimination of B-cell epitopes is a promising approach to the production of less immunogenic proteins for therapeutic purposes...
  11. ncbi Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein
    Noriko Sato
    Nuclear Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Nucl Med 46:1201-9. 2005
    ..The specific activity of DOTA-biotin had a significant effect on its tumor uptake. Therapeutic tumor doses were obtained without dose-limiting toxicity...
  12. ncbi HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity
    Sookhee Bang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1545-50. 2005
    ..Because HA22 (R490A) has increased antitumor activity without increased animal toxicity, immunotoxins with this mutation are candidates for clinical development...
  13. ncbi PAGE4 is a cytoplasmic protein that is expressed in normal prostate and in prostate cancers
    Carlo Iavarone
    Laboratory of Molecular Biology, Clinical Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Mol Cancer Ther 1:329-35. 2002
    ..Furthermore, cDNA microarray analysis indicates that the expression of lipoprotein lipase, a gene frequently deleted in prostate cancer, is down-regulated in a cell line that expresses PAGE4...
  14. ncbi Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 12:4225-31. 2006
    ..To establish monoclonal antibodies (mAb) against megakaryocyte potentiation factor (MPF) and detect MPF in the blood of patients with mesothelioma...
  15. ncbi Selective POTE paralogs on chromosome 2 are expressed in human embryonic stem cells
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Stem Cells Dev 17:325-32. 2008
    ..There is no detectable POTE gene expression in fetal tissues (ages 16-36 weeks). The POTE paralogs that are expressed in ES cells may have a specific function during lineage-specific differentiation of ES cells...
  16. ncbi NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 101:3059-64. 2004
    ..Because of its selective expression in prostate cancer and its presence on the cell surface, NGEP-L is a promising target for the antibody-based therapies of prostate cancer...
  17. ncbi Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin
    Zhengsheng Yao
    Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3137-46. 2004
    ..CONCLUSIONS: (213)Bi-DOTA-biotin, directed by the Pretarget method to tumor-targeted B3-SA, showed a therapeutic effect, although the therapeutic index was low. The source of the toxicity was most likely related to the renal toxicity...
  18. ncbi The T cell receptor gamma chain alternate reading frame protein (TARP), a prostate-specific protein localized in mitochondria
    Hiroshi Maeda
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    J Biol Chem 279:24561-8. 2004
    ..These data demonstrate that TARP is the first prostate-specific protein localizing in mitochondria and indicate that TARP, an androgen-regulated protein, may act on mitochondria to carry out its biological functions...
  19. ncbi Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1104, USA
    Clin Cancer Res 16:1894-903. 2010
    ..We conducted the first preclinical and phase I clinical studies of BL22 in that setting...
  20. ncbi New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
    Clin Cancer Res 11:5840-6. 2005
    ....
  21. ncbi A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
    John E Weldon
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4264, USA
    Blood 113:3792-800. 2009
    ..We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins...
  22. ncbi Evolution and expression of chimeric POTE-actin genes in the human genome
    Yoomi Lee
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Proc Natl Acad Sci U S A 103:17885-90. 2006
    ..These data demonstrate that insertion of a retroposon produced an altered functional POTE gene. This example indicates that new functional human genes can evolve by insertion of retroposons...
  23. ncbi FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins
    Xing Du
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Blood 111:338-43. 2008
    ..Our results suggest that anti-FCRL1 immunotoxin E9(Fv)-PE38 exhibits remarkably specific cytotoxicity and merits further evaluation for the treatment of FCRL1-positive malignancies, including CLL, HCL, FL, MCL, and other B-NHL...
  24. ncbi Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4)
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
    Int J Cancer 121:595-605. 2007
    ..The studies reported here are the first to describe a PAGE4 CTL epitope and its agonist epitope, and thus identify PAGE4 as a potentially useful target for vaccine-mediated therapy of prostate cancer...
  25. ncbi A novel high-affinity human monoclonal antibody to mesothelin
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Int J Cancer 128:2020-30. 2011
    ..Most importantly, because the HN1 immuntoxin kills mesothelin-expressing cancer cells with high cytotoxic activity, we believe that it has significant potential for mesothelin-expressing cancer treatment and diagnosis...
  26. ncbi The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan
    Seiji Kawa
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    MAbs 3:479-86. 2011
    ..47 ± 0.090 ng/ml, IC 50(N34A): 0.048 ± 0.018 ng/ml)-fold compared to WT immunotoxin. The present study suggests that the N34A mutant of scdsFv-HA22-LR could have important consequences in a clinical setting...
  27. ncbi Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-4264, USA
    Clin Cancer Res 12:4695-701. 2006
    ..This effect is not secondary to increased tumor uptake of the immunotoxin. Synergy could be due to improved immunotoxin distribution within the tumor or could involve factors released by other cell types in the tumors...
  28. ncbi Palmitoylation of POTE family proteins for plasma membrane targeting
    Sudipto Das
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Biochem Biophys Res Commun 363:751-6. 2007
    ..Multiple palmitoylation in the small CRRs can result in the strong association of whole POTEs with plasma membrane...
  29. ncbi Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level
    Sudipto Das
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Cancer Res 68:6306-12. 2008
    ..Our findings on the expression and the orientation of the NGEP protein serve as an important framework for the development of mAb targeting the extracellular regions of NGEP that could be used for prostate cancer immunotherapy...
  30. ncbi Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Proc Natl Acad Sci U S A 108:5742-7. 2011
    ..HA22-LR-8M also has greatly reduced antigenicity when exposed to sera from patients who have produced antibodies to HA22. The properties of HA22-LR-8M make it an excellent candidate for further clinical development...
  31. ncbi A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Cancer Res 70:1082-9. 2010
    ..Further, we suggest one basis to understand why chemotherapy and antibody-based therapies cooperate when combined in cancer treatment...
  32. ncbi Mesothelin expression in human lung cancer
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 13:1571-5. 2007
    ..To investigate mesothelin as a new target for immunotherapy in lung cancer...
  33. ncbi POTE paralogs are induced and differentially expressed in many cancers
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
    Cancer Res 66:52-6. 2006
    ..It is likely that POTE has a unique role in primate biology...
  34. ncbi Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2983-90. 2009
    ..To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL...
  35. ncbi Expression of POTE protein in human testis detected by novel monoclonal antibodies
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Biochem Biophys Res Commun 365:603-8. 2008
    ..By immunohistochemistry we demonstrated that the POTE protein is expressed in primary spermatocytes, implying a role in spermatogenesis...
  36. ncbi Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:447-53. 2006
    ..To determine whether mesothelin, a cell surface protein highly expressed in mesothelioma and ovarian cancer, is shed into serum and if so to accurately measure it...
  37. ncbi Immunotoxins in the treatment of refractory hairy cell leukemia
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Hematol Oncol Clin North Am 20:1137-51, viii. 2006
    ..Both agents, termed LMB-2 and BL22, respectively, have been tested in patients who have HCL after failure of purine analogs and other therapies; major responses have been achieved in most patients...
  38. ncbi Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P
    Robert J Kreitman
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 15:5274-9. 2009
    ..To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin...
  39. ncbi Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins
    Kristi A Egland
    Laboratory of Molecular Biology and Cancer Genomics Office, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:1099-104. 2003
    ..Further analysis of this library should yield additional gene products of use in the diagnosis or treatment of breast or prostate cancer...
  40. ncbi Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction
    Evgeny Arons
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA
    Clin Cancer Res 12:2804-11. 2006
    ..Thus, patient-specific RQ-PCR is the most sensitive test for MRD in HCL patients and could be used to determine maximal response in patients obtaining multiple cycles of nonmyelotoxic biological treatment for this disease...
  41. ncbi Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Chem Lab Med 44:594-602. 2006
    ..The membrane form is highly expressed on the surface of hairy cell leukemia (HCL) cells from patients. This study aimed to develop immunoassays for soluble IRTA2/FcRH5 proteins in human serum...
  42. ncbi Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody
    Xing Du
    Laboratory of Molecular Biology, Center for Cancer Research, and Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:5926-34. 2011
    ..Pancreatic cancers express mesothelin and are known to be resistant to most chemotherapeutic agents. The goal of this study is to treat pancreatic cancer with RIT by targeting mesothelin...
  43. ncbi Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 11:3814-20. 2005
    ..Here we addressed the issue of whether mesothelin elicits a humoral immune response in patients with mesothelioma and ovarian cancer...
  44. ncbi Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments
    Satoshi Nagata
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
    Clin Cancer Res 8:2345-55. 2002
    ..Two of these showed good cytotoxic activity to various CD30-positive cell lines. These newly produced immunotoxins should be additionally evaluated for the treatment of CD30-positive lymphomas...
  45. ncbi Pulsed high-intensity focused ultrasound enhances uptake of radiolabeled monoclonal antibody to human epidermoid tumor in nude mice
    Alfia Khaibullina
    Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Nucl Med 49:295-302. 2008
    ..The aim of this study was to determine if pulsed high-intensity focused ultrasound (HIFU) exposures could enhance tumor uptake of (111)In-MX-B3, a murine IgG1kappa monoclonal antibody directed against the Le(y) antigen...
  46. ncbi NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells
    Sudipto Das
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Cancer Res 67:1594-601. 2007
    ..Our results suggest that NGEP-L has a role in promoting cell contact-dependent interactions of LNCaP prostate cancer cells and also that NGEP is a promising immunotherapy target for prostate cancer...
  47. ncbi Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice
    David Filpula
    Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Bioconjug Chem 18:773-84. 2007
    ..Since the bioconjugates can also exhibit the attributes of passive targeting via enhanced permeability and retention, this is the first demonstration of a pivotal role of active targeting for immunotoxin bioconjugate efficacy...
  48. ncbi New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells
    Xing Du
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    J Immunother 30:607-13. 2007
    ..In conclusion, 26292(Fv)-PE38-KDEL shows good cytotoxic activity against CD123 expressing cell lines, and merits further development for the possible treatment of acute myeloid leukemia and other CD123 expressing malignancies...
  49. ncbi Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors
    Yujian Zhang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 104:17099-104. 2007
    ....
  50. ncbi In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute/NIH, 37 Convent Drive, Bethesda, MD 20892-4264, USA
    Cancer Res 64:1419-24. 2004
    ..These results make 8H9(dsFv)-PE38 a candidate for further development as a therapeutic agent for breast cancers, osteosarcomas, and neuroblastomas...
  51. ncbi A guide to taming a toxin?-?recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
    John E Weldon
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    FEBS J 278:4683-700. 2011
    ..This review summarizes our current understanding of PE, its intoxication pathway, and the ongoing efforts to convert this toxin into a treatment for cancer...
  52. ncbi A primate-specific POTE-actin fusion protein plays a role in apoptosis
    Xiu Fen Liu
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Apoptosis 14:1237-44. 2009
    ..Our data indicates that the POTE gene family encodes a new family of proapoptotic proteins...
  53. ncbi The PATE gene is expressed in the accessory tissues of the human male genital tract and encodes a secreted sperm-associated protein
    Angel A Soler-García
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Reproduction 129:515-24. 2005
    ....
  54. ncbi Recombinant immunotoxins for treating cancer
    David J FitzGerald
    Laboratory of Molecular Biology, CCR, National Cancer Institute, Bethesda, MD 20892, USA
    Int J Med Microbiol 293:577-82. 2004
    ..Candidate molecules with favorable characteristics are then evaluated in clinical trials. Here we report on the initial evaluation of BL22, a recombinant immunotoxin targeted to CD22 expressed on the surface of B-cell malignancies...
  55. ncbi In vitro antibody affinity maturation targeting germline hotspots
    Mitchell Ho
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 525:293-308, xiv. 2009
    ..Here, we describe procedures for germline hotspot mutagenesis with an emphasis on strategies for randomizing hotspots with PCR and phage display, using as an example the anti-CD22 monoclonal antibody...
  56. ncbi DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins
    Satoshi Nagata
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr, Rm 5106, Bethesda, MD 20892-4264, USA
    J Immunol Methods 280:59-72. 2003
    ..The large number of MAbs that react with high affinities to a variety of epitopes on the native form of antigens indicates that the method presented in this paper could be generally useful for generating MAbs to other membrane proteins...
  57. ncbi Mammalian cell display for antibody engineering
    Mitchell Ho
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 525:337-52, xiv. 2009
    ..Flow cytometry enhances the screen's sensitivity thereby allowing us to isolate high-affinity antibodies...
  58. ncbi Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Lung Cancer 68:455-9. 2010
    ..MORAb-009 is a chimeric anti-mesothelin monoclonal antibody...
  59. ncbi Identification of novel human CTL epitopes and their agonist epitopes of mesothelin
    Junko Yokokawa
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:6342-51. 2005
    ..CONCLUSIONS: The identification of novel CTL agonist epitopes supports and extends observations that mesothelin is a potential target for immunotherapy of pancreatic and ovarian cancers, as well as mesotheliomas...
  60. ncbi Approach to the patient after relapse of hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Leuk Lymphoma 50:32-7. 2009
    ..An improved high-affinity version of BL22, termed HA22, is currently undergoing phase I testing...
  61. ncbi Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy
    Evgeny Arons
    Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Immunol Immunother 55:1100-10. 2006
    ....
  62. ncbi Non-AUG translational initiation of a short CAPC transcript generating protein isoform
    Suresh Anaganti
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5110, Bethesda, MD 20892 4264, USA
    Biochem Biophys Res Commun 380:508-13. 2009
    ..5 kDa. N-terminal amino acid sequencing of the purified 7.5 kDa protein product indicated that translation starts at the codon for cysteine on the S..
  63. ncbi In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 280:607-17. 2005
    ..Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation...
  64. ncbi A model for obesity and gigantism due to disruption of the Ankrd26 gene
    Tapan K Bera
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Proc Natl Acad Sci U S A 105:270-5. 2008
    ..These results show that alterations in an unidentified gene can lead to obesity and identify a molecular target for the treatment of obesity...
  65. ncbi Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2
    Peter Attia
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother (1997) 29:208-14. 2006
    ..The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T(reg) cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches...
  66. ncbi Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display
    Giuliana Salvatore
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
    Clin Cancer Res 8:995-1002. 2002
    ..The THW mutant had a 5- to 10-fold increase in activity on various CD22-positive cell lines and was up to 50 times more cytotoxic to cells from patients with chronic lymphocytic leukemia and hairy-cell leukemia...
  67. ncbi Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:6398-405. 2011
    ..Moreover, protein engineering is being used to increase its activity, decrease nonspecific side effects, and remove B-cell epitopes...
  68. ncbi Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:82-6. 2011
    ..In separate randomized trials, rituximab is undergoing phase II testing with cladribine for early HCL and with bendamustine or pentostatin for multiply relapsed HCL...
  69. ncbi Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 16:6132-8. 2010
    ..5 to 400 mg/m(2). Disease evaluation with computed tomography occurred on day 35. Subjects with responding or stable disease could receive additional cycles of MORAb-009...
  70. ncbi Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737
    David J FitzGerald
    Laboratory of Molecular Biology, CCR, National Cancer Institute, NIH, HHS, Bethesda, MD, USA
    Leuk Lymphoma 52:79-81. 2011
    ..Expression of high levels of prosurvival Bcl-2 proteins may contribute to toxin resistance...
  71. ncbi Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
    ....
  72. ncbi Localization of mesothelin in epithelial ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Appl Immunohistochem Mol Morphol 13:243-7. 2005
    ..Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin...
  73. ncbi Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 23:6719-29. 2005
    ..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin...
  74. ncbi Mesothelin: a new target for immunotherapy
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:3937-42. 2004
    ..There is evidence that mesothelin is an immunogenic protein and could be exploited as a therapeutic cancer vaccine. A soluble mesothelin variant has been identified and could be a useful tumor marker for malignant mesotheliomas...
  75. ncbi Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 10:16-8. 2004
    ..The development of human antibodies against LMB-1 was detected using a serum neutralization and ELISA...
  76. ncbi Immunotoxins containing Pseudomonas exotoxin A: a short history
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, 37 Convent Drive, Room 5106, Bethesda, MD 20892-4268, USA
    Cancer Immunol Immunother 52:338-41. 2003
  77. ncbi Immunobiological treatments of hairy-cell leukaemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5106, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 16:117-33. 2003
    ..The unlabelled mAb rituximab has also been reported to induce responses in the majority of HCL patients treated, and several CRs have been observed...
  78. ncbi Immunotoxins in cancer therapy
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Curr Opin Investig Drugs 3:1089-91. 2002
    ..Unfortunately, most antibodies do not kill cancer cells unless they are armed with a cytotoxic agent, such as a radioisotope, a cytotoxic drug, or a protein toxin. Each of these have advantages and disadvantages...
  79. ncbi Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis
    Louise McHugh
    Laboratory of Biochemistry, National Cancer Institute/National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    J Biol Chem 277:34383-90. 2002
    ..Such site-directed mutants may increase the utility of immunotoxins for reducing or eradicating persistent HIV-1 infection in humans...
  80. ncbi Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase
    Giuliana Salvatore
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264, USA
    Biochem Biophys Res Commun 294:813-7. 2002
    ....
  81. ncbi BL22 and lymphoid malignancies
    Robert J Kreitman
    Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 19:685-99. 2006
    ..Already under way are a phase-II trial in HCL and phase-I trials in chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) administering BL22 in a modified protocol in an effort to prevent HUS...
  82. ncbi Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 13:5144-9. 2007
    ..To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers...
  83. ncbi Immunotoxins in the treatment of hematologic malignancies
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Curr Drug Targets 7:1301-11. 2006
    ..Several other recombinant immunotoxins are undergoing preclinical development for other target antigens expressed on hematologic malignancies...
  84. ncbi Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma
    Zhuqing Li
    Laboratory of Immunology, National Eye Institute and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 66:10586-93. 2006
    ..The results of B cell-specific immunotoxin therapy may have clinical implications in treating human PIOL...
  85. ncbi Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification. 1. Properties of mutant molecules
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5106, Bethesda, Maryland 20892-4264, USA
    Bioconjug Chem 14:480-7. 2003
    ..Our data indicate that replacement of lysine residues can be achieve without loss of biological potency. These molecules are a useful starting point to carry out site-specific PEGylation experiments...
  86. ncbi Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia
    Francis Mussai
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Br J Haematol 150:352-8. 2010
    ..These results provide a strong rationale for clinical testing of this agent in children with drug-resistant ALL and offers the potential to reduce morbidities of treatment while improving outcome...
  87. ncbi Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers
    Kristi A Egland
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Mol Cancer Ther 1:441-50. 2002
    ..Because XAGE-1 is expressed in such a diverse range of cancers, it has potential to be used as a target for many cancer immunotherapies...
  88. ncbi Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1
    Xing Du
    Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Mol Cell Biol 30:3444-52. 2010
    ..Overexpression of Mcl-1 and Bcl-x(L) inhibited PE-induced MEF death. Our data suggest that Bak is the preferential mediator of PE-mediated apoptosis and that the rapid degradation of Mcl-1 unleashes Bak to activate apoptosis...
  89. ncbi Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin
    Zhengsheng Yao
    Nuclear Medicine Department of the Warren G. Magnuson Clinical Center, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:5755-60. 2002
    ....
  90. ncbi Recombinant immunotoxins in the treatment of cancer
    Ira Pastan
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Methods Mol Biol 248:503-18. 2004
  91. ncbi Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents
    Insook Kim
    Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1180, USA
    Nucl Med Biol 29:795-801. 2002
    ..The reduced renal uptake was also reflected in the reduced whole-body retention, indicating that lowering the pI inhibited the tubular reabsorption of the labeled dsFv...
  92. ncbi Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro
    Raffit Hassan
    Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
    Clin Cancer Res 8:3520-6. 2002
    ..Our results also show low concentrations of an immunotoxin targeting mesothelin is cytotoxic to mesothelin-expressing human tumors by inducing apoptosis...
  93. ncbi Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin
    Dominic Fan
    Department of Cancer Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 1:595-600. 2002
    ..Our data indicate that mesothelin-producing squamous cell carcinoma of the lung may be a good target for this immunotoxin...
  94. ncbi Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin
    Raffit Hassan
    Morphotek Inc, 210 Welsh Pool Road, Exton, PA, USA
    Cancer Immun 7:20. 2007
    ..We have in fact initiated a Phase I clinical study enrolling patients with mesothelin-positive pancreatic, mesothelioma, non-small cell lung and ovarian cancers...
  95. ncbi Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells
    Daniel Steinbach
    University Children s Hospital Jena, Germany
    Eur J Haematol 79:281-6. 2007
    ..SS1(dsFv)PE38 is a recombinant anti-mesothelin immunotoxin which is undergoing clinical evaluation in patients with mesothelin-expressing tumors...
  96. ncbi Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin
    John H Sampson
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    AJR Am J Roentgenol 188:703-9. 2007
    ..Our purpose was to test the hypothesis that hyperintense signal changes on T2-weighted images produced by such infusions can be used to track drug distribution...
  97. ncbi Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
    Jennifer A A Gubbels
    Department of Obstetrics and Gynecology, University of Wisconsin Madison, Madison, USA
    Mol Cancer 5:50. 2006
    ..Here we have addressed this deficit and provide further evidence supporting the role of the MUC16-mesothelin interaction in facilitating cell-cell binding under conditions that mimic the peritoneal environment...
  98. ncbi Mesothelin is shed from tumor cells
    Mitchell Ho
    Cancer Epidemiol Biomarkers Prev 15:1751. 2006
  99. ncbi Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
    Paul E Kennedy
    Laboratory of Viral Diseases, NIAID, National Institutes of Health Building 4, Room 237 Bethesda, MD 20892, USA
    J Leukoc Biol 80:1175-82. 2006
    ..These findings highlight the potential use of 3B3(Fv)-PE38 for depleting HIV-infected cell reservoirs persisting in the face of HAART...
  100. ncbi Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia
    Daniel Steinbach
    University Children s Hospital Jena, Jena, Germany
    Clin Cancer Res 12:2434-41. 2006
    ..It is used for risk-adapted therapy and for the recognition of pending relapses. In acute myeloid leukemia (AML), there is still a need for more suitable MRD markers...
  101. ncbi Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity
    Xing Du
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Cancer Res 68:6300-5. 2008
    ..Our results show that the rapid internalization of large amounts of BL22 bound to CD22 makes CD22 a better therapeutic target than CD19 for immunotoxins and probably for other immunoconjugates that act inside cells...